The primary purpose of this study is to evaluate the pharmacodynamics of single oral doses of PF-05175157 in healthy volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
22
One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
Pfizer Investigational Site
Baton Rouge, Louisiana, United States
Changes in carbohydrate and lipid metabolism
Time frame: 24 hours
Pharmacokinetics: 0.5, 1, 1.5, 2.5, 6.5, 10.5, 24 hrs after dosing, parameters: Cmax, Tmax and Area under the Curve (AUC)
Time frame: 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.